PPLPHARMA · NSE
Piramal Pharma Limited
₹208.16
+1.69% (+₹3.45)
Prev. close
₹204.71
Volume
29,26,602
Delivery %
51.2%
As of
18 Sept 2026
Price history
Dharmesh Shah · ICICI Securities · 06 Jul 2026
“Bullish on Piramal Pharma, recommending a buy at ₹172–176 with a target of ₹188 and a stop-loss at ₹167. After five quarters of underperformance, the stock is forming a higher base above a falling trendline breakout, with a bullish crossover in the weekly stochastic oscillator confirming a resumption of the uptrend and a positive bias.”
Entry ₹172–₹176Target ₹188 (+6.8%)Stop ₹167 (-5.1%)R:R 1.3:1Stopped out · 08 Jul 2026
Analyst sentiment
Analysts lean bullish
2 analyst stances · last 90 days · one per analyst
Trackable
2 · 2 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Bullish on Piramal Pharma for intraday trading; recommends buying at ₹210.50 with a target of ₹223 and a stop loss at ₹2…” | Vaishali ParekhPrabhudas Lilladher | Piramal Pharma | MISS | ||||
| “Recommends buying Piramal Pharma in the range of ₹172-176, with a target price of ₹188 and a stop loss at ₹167. This rec…” | Dharmesh ShahICICI Securities | Piramal Pharma | NOT GRADED | ||||
| “Bullish on Piramal Pharma, recommending a buy at ₹172–176 with a target of ₹188 and a stop-loss at ₹167. After five quar…” | Dharmesh ShahICICI Securities | Piramal Pharma | NOT GRADED | ||||
“Bullish on Piramal Pharma, recommending a buy at ₹172–176 with a target of ₹188 and a stop-loss at ₹167. After five quarters of underperformance, the stock is forming a higher base above a falling trendline breakout, with a bullish crossover in the weekly stochastic oscillator confirming a resumption of the uptrend and a positive bias.” This call couldn't be objectively graded against market data. | |||||||
Fundamentals
About Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, and other generic and speciality products; and analgesics, skin care, vitamin and mineral supplement, kids' wellness, digestives, and women's health, as well as geriatric care. In addition, the company operates as a contract development and manufacturing organization, providing process development, scale-up, and GMP manufacturing services for vaccines and biologics. The company was incorporated in 2020 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Peter Daniel DeYoung
Headquarters
Mumbai
Employees
7,120
Website
piramalpharma.comExchange
View on NSE ↗Key stats
Market cap
₹27,581.59 Cr
Dividend yield
0.08%
EPS (TTM)
₹-2.35
Beta (1Y · daily vs NIFTY 50)
1.16
Beta (5Y · monthly vs NIFTY 50)
1.46
Shares float
61.18 Cr
EPS · quarter ended Jun 2026
₹-0.52
Upcoming earnings
04 Nov 2026
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹7,081.55 Cr | ₹8,171.16 Cr | ₹9,151.18 Cr | ₹8,869.08 Cr | |
| EBITDA | ₹894.25 Cr | ₹1,366.81 Cr | ₹1,648.91 Cr | ₹993.53 Cr |
| ₹-186.46 Cr | ₹17.82 Cr | ₹91.13 Cr | ₹-325.94 Cr | |
| Diluted EPS | ₹-1.54 | ₹0.14 | ₹0.68 | ₹-2.46 |
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹14,522.56 Cr | ₹15,311.81 Cr | ₹15,677.59 Cr | ₹17,965.04 Cr | |
| ₹5,637.08 Cr | ₹4,710.16 Cr | ₹4,856.47 Cr | ₹5,674.58 Cr | |
| Stockholders' equity | ₹6,773.50 Cr | ₹7,911.37 Cr | ₹8,125.47 Cr | ₹8,162.62 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹483.89 Cr | ₹1,004.54 Cr | ₹892.30 Cr | ₹1,652.59 Cr | |
| Investing cash flow | — | ₹-1,338.78 Cr | ₹-434.01 Cr | ₹-477.46 Cr | ₹-826.03 Cr |
| — | ₹817.79 Cr | ₹-422.36 Cr | ₹-440.83 Cr | ₹-38.97 Cr | |
| Capital expenditure | — | ₹-964.75 Cr | ₹-712.04 Cr | ₹-664.38 Cr | ₹-890.02 Cr |
| End cash position | — | ₹53.23 Cr | ₹219.19 Cr | ₹182.32 Cr | ₹976.26 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Oct 22 | Dec 22–Jun 23(3Q) | Aug 23 | Sep 23–Dec 23(3Q) | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 34.79% | 34.79% | 35.02% | 35.02% | 35.02% | 34.95% | 34.95% | 34.95% | 34.95% | 34.86% | 34.86% | 34.86% | 34.86% | 34.80% |
| Public | 64.81% | 64.82% | 64.59% | 64.60% | 64.61% | 64.58% | 64.61% | 64.65% | 64.71% | 64.57% | 64.63% | 64.70% | 64.81% | 64.72% |
| Employee trusts | 0.40% | 0.39% | 0.39% | 0.38% | 0.37% | 0.47% | 0.45% | 0.40% | 0.34% | 0.57% | 0.51% | 0.44% | 0.34% | 0.48% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Piramal Pharma Limited | ₹27,124.45 Cr | ₹208.16 | — | 3.32 | -4.0% | 0.70 | -3.3% | +2.4% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
26 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.